Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Look into the Future of Chronic Pain Management

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief solutions — particularly through its slow-release injection technology. This cutting-edge approach delivers synthetic Cannabidi...
Research | 2 days ago |

NervGen Pharma: Proof that NVG-291 works?

It’s arguably a Eureka moment for investors in NervGen Pharma (TSX.V: NGEN) (OTCQB: NGENF). Tantalizing anecdotal “evidence” has just been published that suggests that NervGen’s prospective wonder-drug — NVG-29...
Knox Henderson | December 23, 2024 |

NurExone Biologic announces important test results

By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...
Research | December 11, 2024 |

The company revolutionizing access to care and natural remedies

The Market Online recently spoke with Liz Viccars, CEO of AJA Health and Wellness Inc. (TSXV:AJA) a company transforming healthcare with its total health access service offering telemedicine, diagnostics and specialized care via proprietary tech. Additionally, AJA Heal...
Coreena Robertson | November 18, 2024 |

Buzz on the Bullboards: TSX hits new high amid holiday optimism and sector disparities

This past week, the TSX reached a new intraday high, reflecting a buoyant market sentiment as investors gear up for the holiday season. However, the rally has highlighted a significant divide among various indices, with some sectors outperforming others. As the fes...
Jonathon Brown | November 14, 2024 |

Buzz on the Bullboards: TSX stocks to watch after Trump’s win

The past week the TSX and Wall Street saw a significant surge following Donald Trump’s return to the presidency. This political shift is expected to have profound implications for various sectors, particularly the financial and energy industries. Inv...
Jonathon Brown | November 7, 2024 |

Buzz on the Bullboards: Mining, tech and cannabis make waves

Canada’s main stock index started the week on a positive note after a rough performance last week, only to pivot downward throughout the following days, suffering declines across major sectors. The Bank of Canada’s reduction of its target ...
Jonathon Brown | July 25, 2024 |

Revolutionary biopharma company makes waves across the globe

The following is a transcription of the above video, and The Market Online has edited it for clarity . The Market Online recently caught up with NurExone Biologic Inc (TSXV:NRX) , a revolutionary biopharmaceutical company developing regenerative medicine therapies,...
Lyndsay Malchuk | July 10, 2024 |

Buzz on the Bullboards: Whose stocks sizzle during summer holidays?

As we get through the summer holiday season, the typically calmer market environment presents a prime opportunity for investors to evaluate their portfolios and consider new investments. The TSX continues to offer a variety of promising stocks, particularly in energ...
Jonathon Brown | July 4, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |
1 2 3 4 5 6 7 8 9 10 ...